Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) revealed on Wednesday that it has completed the acquisition of Stability Inc d/b/a Stability Biologics for a purchase price of USD10m at closing.

The purchase price of USD10m is comprised of 60% cash and 40% stock, plus assumed debt, with future contingent consideration to be paid through a two-year earn out arrangement based on the 2016 and 2017 performance of the Stability Biologics business.

Following closing, Stability Biologics will operate as a wholly owned subsidiary of MiMedx.

Stability Biologics is a provider of human tissue products to surgeons, facilities and distributors serving the surgical, spine and orthopedics sectors of the healthcare industry. It has developed an innovative proprietary platform in bioactive bone graft products and tissue allografts including structural/particulate bone, tendons/ligaments, structural allografts, demineralized bone matrix (DBM) and skin products for burns and traumatic wound care.

In conjunction, MiMedx has affirmed its expectations for the transaction to be accretive to full year 2016 adjusted EPS and its conservative projection for the 2016 Stability Biologics revenues from its processed tissue and bone product sales and distribution to be at least USD15m.